CZ VACCINES closed 2019 financial year with a 4,3% increase in annual turnover, compared to 2018.

    • The clostridial vaccine areas and the Johne’s disease vaccine are the categories that have grown the most.
    • The company maintains a steady growth of 20% since 2015.

 

Porriño (Spain) 20th February, 2020. CZ VACCINES closed 2019 financial year with a 4,3% increase in annual turnover, compared to the previous year. The fastest growing categories have been the Johne’s disease vaccines, with an annual growth of around 21,5%, as well as the range of clostridial vaccines with an increase of 21% over the previous year.

The company maintains a steady growth of 20% since 2015, strengthening its position as one of the leading companies in products derived from mycobacteria, clostridial, bacterial and zoonotic diseases vaccines.

CZ Vaccines is a European-based company focused on vaccines and biotech products and CDMO of biological products and services for third companies.

GUDAIR
The vaccine against the Johne’s disease for small ruminants is the only one vaccine on the market against this disease, providing a lifelong immunity with only one dose in the animal´s life.

Clostridial vaccines
Furthermore, CZ Vaccines is the European leader in the manufacturing of clostridial vaccines, which are distributed in several countries across Europe, Africa, Austria and Latin America.
CZ Vaccines is a company of Zendal.

 

For further information, please contact: Beatriz Díaz, Marketing & Corporate Communication Manager
Email: b.diaz@zendal.com
Tel.: +34 619085074

http://www.czvaccines.com/es/

Compartir: